BGM Group Ltd. (BGM): Cash & Equivalents
$9.82M
As of 2025-09-30
-11.8%
3-year compound annual growth
-3.7%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | $9.82M | 0.0% | 2026-07-21, Balance as of period end |
| 2024-09-30 | $9.82M | +31.3% | 2026-07-21, Balance as of period end |
| 2023-09-30 | $7.48M | -47.8% | 2025-04-03, Balance as of period end |
| 2022-09-30 | $14.32M | +36.8% | 2024-02-15, Balance as of period end |
| 2021-09-30 | $10.47M | -11.8% | 2023-04-19, Balance as of period end |
| 2020-09-30 | $11.87M | +158.3% | 2022-10-13, Balance as of period end |
| 2019-09-30 | $4.59M | n/a | 2021-03-09, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| BGM Group Ltd. (BGM) | 2025-09-30 | $9.82M | 0.0% |
| Lftd Partners Inc. (LIFD) | 2025-12-31 | $1.77M | -17.7% |
| Earth Science Tech, Inc. (ETST) | 2026-03-31 | $796.8K | -45.9% |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $30.15M | -34.9% |
| Bioharvest Sciences Inc. (BHST) | 2025-12-31 | $23.02M | +863.4% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $6.39M | +8.2% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $602.07M | +99.3% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $137.53M | +148.7% |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $4.47M | +23.7% |
Compare BGM, LIFD, ETST, VRCA side by side · Screen every company in Pharmaceutical Preparations ↗